autologous cd34 positive cells transduced with a lentiviral vector containing human was gene
Cell therapyexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 20, 2010 (NCT01515462)
Timeline
Indications
Studied for
Mechanism of action
- Unspecified targetTissue restoration
Tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous cd34 positive cells transduced with a lentiviral vector containing human was gene
- autologous cd34 positive cells transduced with was encoding lentiviral vector.
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01347346 | Phase 1/Phase 2 (Phase 2) | May 1, 2011 | Genethon, University of Paris |
| NCT01347242 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2011 | Genethon, National Institutes of Health (NIH), University of London |
| NCT01515462 | Phase 2 | Apr 20, 2010 | GlaxoSmithKline |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genethon | For profit | 2 | 2 | 1 | 2011 |
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2010 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2011 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of Paris | Academic/Hospital | 1 | 0 | 1 | 2011 |
5 organizations
Page 1 / 1